Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Cates, Christopher J ^a   Lasserson, Toby J ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; STEROID; TERBUTALINE;

ASTHMA; BODY HEIGHT; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EVENING DOSAGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LUNG FUNCTION; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 70349254245     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007313.pub2     Document Type: Review

References (76)

1. * AstraZeneca (D5890L00011). DESOLO - SiT Peri-Launch: a comparison of symbicort single inhaler therapy and conventional best practice for the treatment of persistent asthma in adults. clinicaltrials. gov 2005:http://www.clinicaltrials.gov/ct/show/NCT00252863 [Accessed 3rd September 2008].
2. AstraZeneca (D5890L00008). MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials. gov 2006:http://www.clinicaltrials.gov/ ct/show/NCT00242411 [Accessed 12/04/2006].
3. AstraZeneca (BN-00S-0011). Symbicort single inhaler therapy for asthma in a general practice setting. www.clinicaltrials.gov 2005: http://www. clinicaltrials.gov/ct/show/NCT00235911 [Accessed 22/02/2008].
4. AstraZeneca (D5890L00009). SALTO - symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov 2006:http: //www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008].
5. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research & Opinion 2004;20(9):1403-1418 (Pubitemid 39361344)
6. Sears MR, Boulet L-P, Laviolette M, FitzGerald J Mark, Bai TR, et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal 2008:Epub: doi: 10.1183/09031936.00104007.
7. Sears R, Boulet L-P, Laviolette M, FitzGerald JM, Bai R, SmiljanicGeorijev N, et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal 2006;28(Suppl 50):613s.
8. Sovani MP, Whale CI, Oborne J, Cooper S, Mortimer K, Ekström T, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice 2008;58(546):37-43.
9. Bateman ED, Palmqvist M, Juniper EF, Zhu Y, Ekstrom T. Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed-dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando. 2004.
10. Bruce SA, Scherer YK. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence- Based Nursing 2005;8(3):78.
11. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. European Respiratory Journal. 2001; Vol.18, issue Suppl 33:517s.
12. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001; Vol.18, issue Suppl 33:331s.
13. O'Byrne PM. Acute asthma intervention: Insights from the STAY study. Journal of Allergy & Clinical Immunology 2007;119(6):1332-1336
14. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory & Critical Care Medicine 2005;171 (2):129-136
15. O'Byrne PM, Godard P, PistolesiM, Ekstrom T. Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando. 2004:Poster J93.
16. SD-039-673. Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as Single Therapy in patients with mild-moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http: //www.astrazenecaclinicaltrials.com 2006.
17. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory & Critical Care Medicine 2005;171 (2):129-136
18. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1060.
19. * Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy - a new strategy in pediatric asthma. Chest 2006;130(6):1733-1743
20. O'Byrne PM. Acute asthma intervention: Insights from the STAY study. Journal of Allergy & Clinical Immunology 2007;119(6):1332-1336
21. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory & Critical Care Medicine 2005;171 (2):129-136
22. SD-039-673. Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as Single Therapy in patients with mild-moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http: //www.astrazenecaclinicaltrials.com 2006.
23. Astrazenca (SD-039-0667). Efficacy and Safety of Symbicort® Turbuhaler® as Single Therapy in Patients with Mild to Moderate Asthma - STEAM (SD-039-0667). Astrazeneca Clinical Trials Register 2005:http://www. astrazenecaclinicaltrials.com (accessed 20th February 2008).
24. Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial. Chest 2006;129:245-256 (Pubitemid 43289841)
25. * AstraZeneca (D5890L00014). STYLE - symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov 2005:http: //www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008].
26. Balanzat A, Centanni S, Palmqvist M, Rabe K. Budesonide/ formoterol single inhaler therapy reduces over reliance on rapid acting reliever medication [Abstract]. European Respiratory Journal 2004;24(Suppl 48):344s.
27. Astrazeneca (D5890C00002). Efficacy and safety of Symbicort ® Turbuhaler® 160/4.5 mcg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 mcg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month, randomised, double-blind, parallel-group, active controlled, multinational phase IIIB study in adult and adolescent patients with persistent asthma. AstraZeneca Clinical Trials Register 2006, issue www. astrazenecaclinicaltrials.com (accessed 21/02/2008).
28. Bousquet J, Boulet L-P, Peters MJ, Magnussen H, Quiralte J, Martinez- Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respiratory Medicine 2007;101(12):2437-2446 (Pubitemid 350010579)
29. AstraZeneca. SYM/050/DEC2007. Data on File. Bleecker ER, Postma DS, Lawrance R, Meyers DA, Ambrose H, GoldmanM. Effect of polymorphisms in the beta2-adrenergic receptor gene (ADRB2) on response to long-acting beta2-agonist (LABA) therapy. Journal Allergy and Clinical Immunology 2007;119(2):523.
30. Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Current Medical Research and Opinion 2007;23(8):1867-1878 (Pubitemid 47300386)
31. Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations a higher maintenance dose of budesonide/versus formoterol or salmeterol/ fluticasone. European Respiratory Journal 2006;28(Suppl 50): 205s.
32. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice 2007;61(5):725-736 (Pubitemid 46587876)
33. Price D, Wiren A, Kuna P. Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal 2006;28(Suupl 50):214s.
34. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/ formoterol for maintenance and reliever asthma therapy. Allergy 2007;62(10):1189-1198 (Pubitemid 47374022)
35. Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Current Medical Research and Opinion 2007;23(8):1867-1878 (Pubitemid 47300386)
36. D'Urzo A, Vogeimeier C, Jaspal M, Merino JM, Boulet S. Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life stud. American Thoracic Society International Conference; May 20-25; San Diego, California. 2005:Poster G24.
37. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24(7):695-708. (Pubitemid 43998822)
38. Vogelmeier C, D'Urzo A. Maintenance plus as-needed budesonide/ formoterol vs salmeterol/fluticasone in a real-life setting. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 2770.
39. Vogelmeier C, D'Urzo A, Jaspal M, Merino JM, Johansson G, Boulet S. Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:Poster F67.
40. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal 2005;26(5):819-828 (Pubitemid 41632038)
41. AstraZeneca (D5890C00003). A comparison of the control of asthma inflammation provided by Symbicort tur- buhaler 160/4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 mcg/inhalation bid plus Pulmicort turbuhaler 400mcg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed. www.clinicaltrials.gov 2006:http: //www.clinicaltrials.gov/ct/show/ NCT00244608 [Accessed22/02/2008].
42. Ind PW, Villasante C, Shiner RJ, Pietinalho A, Boszormenyi NG, Soliman S, Selroos O. Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. European Respiratory Journal 2002;20(4):859-866 (Pubitemid 35175121)
43. Jenkins CR, Marks GB, Gibson PG, Wark PAB, Thien FC, Belousova EG, et al. A randomised controlled trial of two algorithms for maintaining asthma control on long-acting bronchodilators (LABA) and inhaled corticosteroids (ICS). Thoracic Society of Australia and New Zealand Annual Scientific Meeting, 25-28 March 2007, Auckland. 2007:Abstract TP044.
44. Jonkers RE, Bantje TA, Aalbers R. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a doubleblind, placebo-controlled study. Respiratory Research 2006;7:141. (Pubitemid 46442928)
45. Loukides S, Papageorgiou M, Karokis A, Zervas E, Christodoulopoulou A, Papageorgiou N, et al. Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FUM) is effective in asthma control. European Respiratory Journal. 2005; Vol.26(Suppl 49):124S.
46. Astrazeneca (LD-039-0003). An open, randomized, parallel-group, multicentre, phase IIIB study to evaluate the efficacy of Symbicort® Turbuhaler® single inhaler therapy (SiT), given as a lowmaintenance dose once or twice daily plus as needed, compared to a higher maintenance dose of Symbicort Turbuhaler given twice daily plus Oxis® Turbuhaler® as needed during 24 weeks in asthmatic patients (LD- 039-0003). AstraZeneca Clinical Trials Register 2006, issue http: //www.astrazenecaclinicaltrials.com/ncmprint. aspx?type=article¶m=516829 (accessed 21st February 2008).
47. Lundborg M, Wille S, Bjermer L, Tilling B, LundgrenM, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a highermaintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Current Medical Research & Opinion 2006;22(5):809-821 (Pubitemid 43875550)
48. Richter K, Hartmann U, Metzenauer P, Magnussen H. Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma. Respiratory Medicine 2007;101 (3):467-475 (Pubitemid 46196330)
49. Rabe F, Atienza T, Magyar P, Larsoon P, Jorup C, Lalloo G. A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma. European Respiratory Journal 2006;28(Suppl 50):666s.
50. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;938(9537):744-753 (Pubitemid 44279053)
51. Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. European Respiratory Journal 2006;28 (4):748-755 (Pubitemid 46331995)
52. Haahtela T, Tamminen K, Malmberg P, Karjalainen J, Yia-Outinen H, Zetterstrom O, et al. As-needed treatment with a b2-agonist/ corticosteroid combination in mild intermittent asthma (SOMA). European Respiratory Journal 2005;26(Suppl 45):Abstract No. 1722.
53. Berggren F, Ekström T. A cost-effectiveness study comparing the asneeded use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma. Respiratory Medicine 2001;98(9): 753-758 (Pubitemid 32923098)
54. Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AGM, Rasidakis A, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357(9252):257-261 (Pubitemid 32120856)
55. NCT00463866. Ongoing study March 2007.
56. NCT00628758. Ongoing study March 2006.
57. Study SPAINA Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel- Group, Multicentre Study. Estimated enrolment: 1000. Ongoing study Sept 2006.
58. SYMPHONIE. Ongoing study Sept 2005.
59. Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
60. Barnes PJ. Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. Bmj 2007; Vol.335, issue 7618:513-.
61. BisgaardH. Effect of long-acting Beta2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology 2003; Vol.36, issue 5:391-398 [: 1099-0496]
62. British Thoracic Society. British Guidelines on Asthma Management. Thorax 2008; Vol.63, issue Suppl 1.
63. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events (Cochrane Review). Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
64. Cates Christopher J, Cates Matthew J, Lasserson Toby J. Regular treatment with formoterol for chronic asthma: serious adverse events. CochraneDatabase of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2]
65. Delea TE, HagiwaraM, Stanford RH, Stempel DA. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clinical Therapeutics 2008; Vol.30, issue 3: 560-571
66. Fitz Gerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J. Doubling the dose of budesonide versusmaintenance treatment in asthma exacerbations. Thorax 2004; Vol.59, issue 7:550-556 (Pubitemid 38901511)
67. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533]
68. HarrisonT, Oborne J, Newton S, Tattersfield A. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; Vol.363, issue 9405:271-275 (Pubitemid 38142409)
69. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
70. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] Available from: www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
71. Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004106.pub3] (Pubitemid 351805468)
72. Lipworth BJ, Jackson C. A SMART choice for primary care asthma therapy?. http://www.bmj.com/cgi/eletters/335/7618/513#178078 13 October 2007.
73. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [Art. No.: CD005535. DOI: 10.1002/14651858.CD005535]
74. PalmqvistM, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulmonary Pharmacology & Therapeutics 2001;14 (1):29-34. (Pubitemid 32158294)
75. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory & Critical Care Medicine 1999;160 (2):594-599
76. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD001385. DOI: 10.1002/14651858. CD001385.pub2]